Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 May 2:6:19.
doi: 10.1186/1756-6606-6-19.

A human Dravet syndrome model from patient induced pluripotent stem cells

Norimichi Higurashi  1 , Taku Uchida, Christoph Lossin, Yoshio Misumi, Yohei Okada, Wado Akamatsu, Yoichi Imaizumi, Bo Zhang, Kazuki Nabeshima, Masayuki X Mori, Shutaro Katsurabayashi, Yukiyoshi Shirasaka, Hideyuki Okano, Shinichi Hirose
Affiliations
Case Reports

A human Dravet syndrome model from patient induced pluripotent stem cells

Norimichi Higurashi et al. Mol Brain. .

Abstract

Background: Dravet syndrome is a devastating infantile-onset epilepsy syndrome with cognitive deficits and autistic traits caused by genetic alterations in SCN1A gene encoding the α-subunit of the voltage-gated sodium channel Na(v)1.1. Disease modeling using patient-derived induced pluripotent stem cells (iPSCs) can be a powerful tool to reproduce this syndrome's human pathology. However, no such effort has been reported to date. We here report a cellular model for DS that utilizes patient-derived iPSCs.

Results: We generated iPSCs from a Dravet syndrome patient with a c.4933C>T substitution in SCN1A, which is predicted to result in truncation in the fourth homologous domain of the protein (p.R1645*). Neurons derived from these iPSCs were primarily GABAergic (>50%), although glutamatergic neurons were observed as a minor population (<1%). Current-clamp analyses revealed significant impairment in action potential generation when strong depolarizing currents were injected.

Conclusions: Our results indicate a functional decline in Dravet neurons, especially in the GABAergic subtype, which supports previous findings in murine disease models, where loss-of-function in GABAergic inhibition appears to be a main driver in epileptogenesis. Our data indicate that patient-derived iPSCs may serve as a new and powerful research platform for genetic disorders, including the epilepsies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Characterization of generated iPSCs and neuronal differentiation. (A) SCN1A sequencing of the indicated cell material. Solid arrowheads point to the c.4933C>T substitution. (B) iPSC morphology and immunostaining of pluripotency markers (Oct 4, Nanog, Tra-1-60, Tra-1-81, and SSEA4 without SSEA1). Scale bar, 500 μm. (C) iPSC-derived teratomas generated in NOD-SCID mouse testes comprised tissues from all three germ layers. Scale bar, 200 μm (neural rosettes and respiratory epithelium) and 400 μm (others). (D) Real-time PCR analysis showed suppressed expression of the four reprogramming factors in both patient and control iPSCs compared to patient fibroblasts transduced with the same four factors (D1-HDF-4F). (E) G-band karyotyping showed normal chromosome numbers (46,XX) in all tested colonies (N = 20 each). (F) Representative images of embryoid bodies (EB) and neurospheres (NS). Scale bar, 500 μm. (G) Expression of βIII-tubulin, a neuronal marker (green) and GFAP, an astrocyte marker (red) in iPSC-derived neural cells. Scale bar, 200 μm. Day numbers indicate the days of differentiation in adherent culture after neurosphere formation.
Figure 2
Figure 2
Nav channel expression in iPSC-derived neurons. (A) Real-time PCR addressing neuronal Nav expression at 30 days of differentiation (N = 3 in each cell line) Crossing point differences to β-actin (ΔCp = Cpβ-actin - CpNav) closer to zero indicate higher expression. PCR efficiencies were nearly identical (Additional file 2). Asterisks indicate a significant difference to SCN1A (P < 0.5, one-way ANOVA). Expression strength of the indicated Nav genes was constant across the cell lines (P = 0.92, two-way ANOVA) (B) Normalized expression levels for each Nav gene (SCN1A + SCN2A + SCN3A + SCN8A)/4 = 1. Compared to the control, SCN1A expression tended to be higher in D1-1 (P = 0.0929, one-way ANOVA), and it was significantly higher in D1-6 (*P = 0.0078). The distribution of Nav genes expression ratios in each cell line was significantly different between the control and the patient lines (P =0.0086 and <0.0001 for D1-1 and D1-6, respectively, two-way ANOVA), but identical between D1-1 and D1-6 (P = 0.11). (C) Sequencing of SCN1A reverse transcribed mRNA isolated from iPSCs-derived neurons. Patient-neurons show a double peak at mutation site (solid arrowheads), confirming the heterozygous state of the cells (D) Immunocytochemical characterization of Nav1.1 expression in control neurons: strong (solid arrows), moderate (open arrows), weak (solid arrowheads), and faint (open arrowhead). Despite weak staining in the cell body, neurite staining was often apparent (solid arrowheads). (E) Neurite co-localization of Nav1.1 and the AIS marker ankyrin G (AnkG, solid arrowheads). (F) PAN-Nav staining of SCN1A Venus-positive neurons (via anti-GFP, see Figure 3) in the AIS (arrowheads). (G) Co-localization of Nav1.1 and GAD67 staining. (H) VGlut1-positive neuron with SCN1A Venus expression. Scale bars: 100 μm (D), 30 μm (F), 200 μm (G) and 50 μm (others).
Figure 3
Figure 3
Structure and characterization of the lentiviral SCN1A-reporter used in the electrophysiological analyses. (A) The reporter comprised (5′ to 3′) a 1.2-kb upstream sequence, a 5′-untranslated exon, the 5′-end of the first coding exon, and, following the ATG start codon, Venus cDNA. (B) & (C) 201B7 neurons labeled for Venus (using a GFP antibody) and Nav1.1 (B) or GABA (C). (B) Open arrowheads indicate GFP-pseudopositive neurons lacking Nav1.1 staining. (C) GFP-positive neurons with (arrowhead) and without GABA staining (open arrowhead). Scale bars: 200 μm.
Figure 4
Figure 4
Electrophysiological characteristics of mature iPSC-derived neurons. (A) Capacitance, resting membrane potential (RMP), action potential (AP) firing threshold, and voltage peak were identical across all neurons analyzed (P >0.05, Kruskal-Wallis test); error bars indicate S.E.M. (B) Representative traces of AP trains triggered by a 500-ms depolarizing current at the indicated intensities. Transverse dotted lines demark 0 mV membrane potential. Scale bars: 20 mV vs. 100 ms. (C) Action potential (AP) decrement at current intensities triggering >10 APs calculated as a percentage: 10th/1st AP amplitude. Control vs. D1-1 (P = 0.078) and D1-6 (*P = 0.045, ANOVA); D1-1 vs. D1-6 (P = 0.839) (D) Total number of APs during the 500-ms stimulation period vs. current injection intensity. When exposed to strong current injections, both patient-derived cell lines produced significantly fewer APs compared to the control (the slope of AP numbers at ≥50 pA, P = 0.0102 and 0.0011 for D1-1 and D1-6, respectively, ANCOVA, *P <0.05 for D1-6 only, **P <0.05 for both D1-1 and D1-6, Wilcoxon rank-sum test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. In: Epileptic syndromes in infancy, childhood and adolescence. 4. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editor. Montrouge: John Libbey Eurotext; 2005. Severe myoclonic epilepsy in infancy (Dravet syndrome) pp. 89–113.
    1. Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52(Suppl 2):44–49. - PubMed
    1. Sakauchi M, Oguni H, Kato I, Osawa M, Hirose S, Kaneko S, Takahashi Y, Takayama R, Fujiwara T. Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia. 2011;52:1144–1149. doi: 10.1111/j.1528-1167.2011.03053.x. - DOI - PubMed
    1. Depienne C, Trouillard O, Saint-Martin C, Gourfinkel-An I, Bouteiller D, Carpentier W, Keren B, Abert B, Gautier A, Baulac S. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet. 2009;46:183–274. - PubMed
    1. Marini C, Scheffer I, Nabbout R, Suls A, De Jonghe P, Zara F, Guerrini R. The genetics of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):24–33. - PubMed

Publication types

MeSH terms